124I-18B10

N/A

Report date: 2025/11/21 17:15:40

Base Information

Drug Name124I-18B10
Drug Alias Name124I-TST001124I-18B10124-I-18-B-10
ClassificationRadiation-emitting products > Nuclides > Iodine > 124IBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsGastrointestinal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesTranscenta Holding LtdBeijing Cancer Hospital
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Cancer Hospital
Inactive CompaniesN/A
Active IndicationsGastrointestinal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A